Tests efruxifermin in adults with cirrhosis caused by fatty liver disease
Tests efruxifermin against a placebo in adults with cirrhosis from MASH.
Plain-language title generated from the registry record
Registry title: A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Key facts
- Where
- Angers, Clichy, Créteil, Le Chesnay, Lille, Limoges, Lyon, Marseille, Montpellier Cedex 5, Nice, Paris, Pessac, Strasbourg, Toulouse, and Vandœuvre-lès-Nancy, FranceSee the 15 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06528314, who can take part
Where in France
- AngersAngers, FranceTaking people
- ClichyClichy, FranceTaking people
- CréteilCréteil, FranceTaking people
- Le ChesnayLe Chesnay, FranceTaking people
- LilleLille, FranceTaking people
- LimogesLimoges, FranceTaking people
- LyonLyon, FranceTaking people
- MarseilleMarseille, FranceTaking people
- Montpellier Cedex 5Montpellier Cedex 5, FranceTaking people
- NiceNice, FranceTaking people
- ParisParis, FranceTaking people
- PessacPessac, FranceTaking people
- StrasbourgStrasbourg, FranceTaking people
- ToulouseToulouse, FranceTaking people
- Vandœuvre-lès-NancyVandœuvre-lès-Nancy, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Akero Therapeutics, Inc
- Trial code
- NCT06528314
- Record updated
- 13 October 2026
- Original description
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Inclusion: Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH and NAS score of >=3 (at least 1 in each category) or evidence of steatosis and 2 current features of metabolic comorbidities; Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH.
Exclusion: Any current or prior history of decompensated liver disease; Other inclusion and exclusion criteria may apply; Type 1 diabetes or unstable Type 2 diabetes; Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.